Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Refractory Inflammatory Bowel Disease.

Karl H. Kim1, Gary R. Lichtenstein

  • 1Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, 3400 Spruce Street, 3rd Floor Ravdin Building, Philadelphia, PA 19104-4283, USA. grl@uphs.upenn.edu

Current Treatment Options in Gastroenterology
|May 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of biological therapy in inflammatory bowel disease.

Drugs of today (Barcelona, Spain : 1998)·2003
Same author

Refractory Inflammatory Bowel Disease.

Current treatment options in gastroenterology·2001
Same journal

Esophageal Disorders in the Older Adult.

Current treatment options in gastroenterology·2025
Same journal

Endobariatrics: a Still Underutilized Weight Loss Tool.

Current treatment options in gastroenterology·2023
Same journal

Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.

Current treatment options in gastroenterology·2023
Same journal

Inflammatory Bowel Disease Therapy and Venous Thromboembolism.

Current treatment options in gastroenterology·2023
Same journal

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment.

Current treatment options in gastroenterology·2023
Same journal

Celiac Disease in the Elderly.

Current treatment options in gastroenterology·2023
See all related articles

Biologic therapies offer new options for refractory ulcerative colitis and Crohn's disease. These advanced treatments, alongside traditional methods, aim to manage severe colonic inflammation and maintain remission effectively.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Refractory colonic inflammation in ulcerative colitis (UC) and Crohn's disease (CD) presents significant treatment challenges.
  • Established therapies include corticosteroids and cyclosporine A for severe UC, and immunomodulators for remission maintenance in UC and CD.

Purpose of the Study:

  • To review current and emerging therapeutic options for refractory colonic inflammation in inflammatory bowel disease (IBD).
  • To highlight the efficacy of biologic therapies in managing severe or refractory cases of UC and CD.

Main Methods:

  • Review of current literature on therapeutic strategies for ulcerative colitis and Crohn's disease.
  • Analysis of the role of biologic agents, immunomodulators, and surgical interventions in IBD management.

Related Experiment Videos

Main Results:

  • Biologic therapies, particularly anti-tumor necrosis factor-alpha monoclonal antibodies, show high efficacy in severe or refractory Crohn's disease.
  • Immunomodulatory drugs like azathioprine, 6-mercaptopurine, and methotrexate are effective for maintaining remission in refractory IBD.
  • Experimental biologics offer alternatives for corticosteroid-dependent or non-responsive patients.

Conclusions:

  • The therapeutic landscape for refractory IBD has expanded with novel biologic agents.
  • A multi-faceted approach combining biologics, immunomodulators, and surgery is crucial for managing complex cases of ulcerative colitis and Crohn's disease.